Infantile Spasms Therapeutics Market , by Drug Type Thumbnail Image

2024

Infantile Spasms Therapeutics Market , by Drug Type

Infantile Spasms Therapeutics Market , by Drug Type (Corticosteroids, Adrenocorticotropic Hormones (ACTH) , Antiepileptic Drugs (AEDs) , Others) , by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033

LS : Healthcare

Select an option
Author's: Monika Darandale | Roshan Deshmukh
Publish Date:

Get Sample to Email

Infantile Spasms Therapeutics Market  Research, 2033

The global infantile spasms therapeutics market size was valued at $162.0 million in 2023, and is projected to reach $223.4 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033. The infantile spasms therapeutics market is driven by the increasing prevalence of infantile spasms, advancements in drug development, and the growing awareness of early diagnosis and treatment options. Additionally, rising investments in pediatric healthcare and ongoing clinical trials for innovative therapies are boosting infantile spasms therapeutics market growth. 

Infantile Spasms Therapeutics Market 

Market Introduction and Definition 

The infantile spasms therapeutics market focuses on treatments for a specific type of epilepsy known as infantile spasms (IS) , which typically manifests in infants and is characterized by sudden, brief contractions of the muscles. These spasms can occur in clusters and may lead to developmental delays and other neurological issues if not effectively managed. The market encompasses a range of therapeutic options, including medications, dietary therapies, and surgical interventions aimed at controlling seizures and promoting normal development. 

As awareness of the condition grows and research advances, the demand for innovative treatments is increasing, leading to significant developments in therapeutic approaches and a growing interest from pharmaceutical companies. This market is critical not only for improving the quality of life for affected children but also for addressing the long-term developmental challenges associated with infantile spasms. 

Key Takeaways 

  • The infantile spasms therapeutics market report study covers 20 countries. The research includes a segment analysis of each country in terms of value ($Million) for the projected period 2023-2033. 
  • More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major infantile spasms therapeutics market industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights. 
  • The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives. 

Key Market Dynamics 

The infantile spasms therapeutics market size is driven by a growing prevalence of epilepsy and related neurological disorders among infants, with studies indicating that infantile spasms affect approximately 2-3 in every 1, 000 live births. The increasing awareness of early diagnosis and treatment options has led to enhanced screening practices, fostering market growth. Moreover, advancements in drug formulations, such as the introduction of ACTH (adrenocorticotropic hormone) and vigabatrin, have improved treatment outcomes, making therapies more effective. 

However, the market faces certain restraints during infantile spasms therapeutics market forecast, including high treatment costs and limited reimbursement options, which may hinder access to necessary medications for some families. Additionally, the market's growth could be affected by the stringent regulatory processes required for drug approval, leading to longer development timelines. 

infantile spasms therapeutics market opportunity abound in the form of ongoing research and development aimed at creating novel therapies. For instance, the rise of biologics and gene therapy presents a promising avenue for more targeted treatment strategies. Furthermore, increasing investments in pediatric healthcare and initiatives by organizations such as the American Epilepsy Society to support research on childhood epilepsy can further stimulate infantile spasms therapeutics market growth. As the global focus on addressing rare diseases intensifies, the infantile spasms therapeutics market is poised for significant growth, with the potential to enhance the quality of life for affected infants and their families. 

Market Segmentation 

The infantile spasms therapeutics industry is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is classified into corticosteroids, adrenocorticotropic hormones (ACTH) , antiepileptic drugs (AEDs) , and others. Based on route of administration, the market is divided into oral and parenteral. Based on distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.  

Regional/Country Market Outlook 

North America has largest infantile spasms therapeutics market share is primarily driven by the increasing incidence of epilepsy and related disorders among infants, with estimates suggesting that infantile spasms account for 2-3% of all epilepsy cases in children. This rising prevalence has led to heightened awareness among healthcare professionals and parents regarding the importance of early diagnosis and intervention, fostering a greater demand for effective treatments.

Additionally, advancements in therapeutic options, such as the approval of new drugs like vigabatrin and the use of corticosteroids, have improved treatment efficacy and safety profiles, making them more appealing to healthcare providers. 

Moreover, significant investments in pediatric research and development by pharmaceutical companies and academic institutions are fueling innovation in treatment options. The presence of robust healthcare infrastructure and access to specialized pediatric neurology services in North America further enhances the ability to diagnose and treat infantile spasms effectively. Regulatory support from agencies like the FDA, which has expedited the approval processes for breakthrough therapies, also contributes to market growth.  

Industry Trends 

  • Continuous research and development are resulting in the introduction of new antiepileptic drugs specifically designed for infants. This includes both existing medications and novel therapies. 
  • There is a trend toward personalized medicine, with treatments being tailored to the specific genetic and metabolic profiles of affected infants. 

Parent Market Overview 

The global epilepsy drugs market size was valued at $7 billion in 2022, and is projected to reach $9.8 billion by 2032, growing at a CAGR of 3.5% from 2023 to 2032. Epilepsy is a neurological disorder that causes recurring seizures due to abnormal electrical activity in the brain. It is a chronic noncommunicable disease. There are many different types of seizures, but all involve involuntary movements that may affect a part of the body or the entire body. 

Treatment options include medication such as first, second and third generation drugs. The exact cause of epilepsy is often unknown, but it can be attributed to various factors, including genetic, brain injury, infections, and prenatal factors. Seizures occur in epilepsy classified into focal seizures, generalized seizures, and non-epileptic seizures. Treatment for epilepsy usually involves antiepileptic medications which help to control seizures. The choice of medication and dosage depends on the type of seizures, age of the patient, overall health, and other factors. 

Global Epilepsy Drugs Market, 2022 & 2032 (in billion)

2022

2032

7

9.8

Source : AMR Analysis

Competitive Landscape 

The major infantile spasms therapeutics market share players operating in the market include Mallinckrodt Pharmaceuticals H. Lundbeck A/S, Pfizer Inc., UCB Pharma S.A., Jazz Pharmaceuticals, Novartis AG, Teva Pharmaceutical Industries Ltd., Zydus Lifesciences Limited, Viatris, AbbVie Inc. Other players in the infantile spasms therapeutics market include Pryos Pharmaceuticals, Catalyst Pharmaceuticals, Amneal Pharmaceuticals, Inc., Upsher-Smith Laboratories, LLC, Marinus Pharmaceuticals and so on. 

Recent Key Strategies and Developments 

  • In June 2024, the U.S. Food and Drug Administration (FDA) has approved a new ready-to-use oral solution of vigabatrin, developed by Pryos Pharmaceuticals, for the treatment of infantile spasms. 
  • In March 2023, Zydus Lifesciences Limited received final approval from the United States Food and Drug Administration (USFDA) for Vigabatrin for Oral Solution USP, 500 mg used to treat infantile spasms in babies and children between the ages of 1 month and 2 years.  

Key Benefits For Stakeholders 

  • This report provides a quantitative analysis of the infantile spasms therapeutics market segments, current trends, estimations, and dynamics of the infantile spasms therapeutics market analysis from 2023 to 2033 to identify the prevailing Infantile spasms therapeutics market opportunities. 
  • The market research is offered along with information related to key drivers, restraints, and opportunities. 
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network. 
  • In-depth analysis of the infantile spasms therapeutics market segmentation assists to determine the prevailing market opportunities. 
  • Major countries in each region are mapped according to their revenue contribution to the global Infantile spasms therapeutics market statistics. 
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players. 
  • The report includes the analysis of the regional as well as global Infantile spasms therapeutics market trends, key players, market segments, application areas, and market growth strategies. 

Key Sources Referred 

  • Centers for Disease Control and Prevention 
  • World Health Organization 
  • National Center for Biotechnology Information 
  • The Lancet 
  • National Perinatal Epidemiology and Statistics Unit (NPESU)  
  • Science Direct 
  • Health Resources and Services Administration (HRSA)  
  • Department of Health and Human Services (HHS)  
  • National Institutes of Health (NIH)  
  • GOV.UK

Infantile Spasms Therapeutics Market , by Drug Type Report Highlights

Aspects Details
icon_1
Market Size By 2033

USD 223.4 Million

icon_2
Growth Rate

CAGR of 3.2%

icon_3
Forecast period

2024 - 2033

icon_4
Report Pages

260

icon_5
By Drug Type
  • Corticosteroids
  • Adrenocorticotropic Hormones (ACTH)
  • Antiepileptic Drugs (AEDs)
  • Others
icon_6
By Route Of Administration
  • Oral
  • Parenteral
icon_7
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_9
Key Market Players

Teva Pharmaceutical Industries Ltd., Pfizer Inc., Viatris Inc., Jazz Pharmaceuticals, Inc., H. Lundbeck A/S, Novartis AG, UCB Pharma S.A., Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc.

Author Name(s) : Monika Darandale | Roshan Deshmukh
Frequently Asked Questions?

The Mallinckrodt Pharmaceuticals H. Lundbeck A/S, Pfizer Inc., UCB Pharma S.A., Jazz Pharmaceuticals, Novartis AG held a high market position in 2023.

The base year is 2023 in infantile spasms therapeutics market.

The forecast period for infantile spasms therapeutics market is 2024 to 2033.

The market value of infantile spasms therapeutics market is projected to reach $223.4 million.

The total market value of infantile spasms therapeutics market was $162 million in 2023.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Infantile Spasms Therapeutics Market , by Drug Type

Global Opportunity Analysis and Industry Forecast, 2024-2033